Begoña Benito

Dr. Begoña Benito


Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
AVAnder Vergara
Ander Vergara
CCConxita Jacobs Cachá
Conxita Jacobs Cachá
CCCarmen Llorens Cebrià
Carmen Llorens Cebrià
AOAlberto Ortiz
Alberto Ortiz
IDIrene Martínez Díaz
Irene Martínez Díaz
MSMaria Jose Soler
Maria Jose Soler
Treatments with sodium–glucose 2 cotransporter inhibitors (SGLT2i) or endothelin receptor antagonists (ERA) have shown cardiorenal protective effects. The present study aimed to evaluate the cardiorenal beneficial effects of the combination of SGLT2i and ERA on top of renin–angiotensin system (RAS) blockade. Type 2 diabetic mice (db/db) were treated with different combinations of an SGLT2i (empagliflozin), an ERA (atrasentan), and an angiotensin-converting enzyme inhibitor (ramipril) for 8 weeks. Vehicle-treated diabetic mice and non-diabetic mice were included as controls. Weight, blood glucose, blood pressure, and kidney and heart function were monitored during the study. Kidneys and heart were collected for histological examination and to study the intrarenal RAS. Treatment with empagliflozin alone or combined significantly decreased blood glucose compared to vehicle-treated db/db. The dual and triple therapies achieved significantly greater reductions in diastolic blood pressure than ramipril alone. Compared to vehicle-treated db/db, empagliflozin combined with ramipril or in triple therapy significantly prevented GFR increase, but only the triple combination exerted greater protection against podocyte loss. In the heart, empagliflozin alone or combined reduced cardiac isovolumetric relaxation time (IVRT) and left atrium (LA) diameter as compared to vehicle-treated db/db. However, only the triple therapy was able to reduce cardiomyocyte area. Importantly, the add-on triple therapy further enhanced the intrarenal ACE2/Ang(1-7)/Mas protective arm of the RAS. These data suggest that triple therapy with empagliflozin, atrasentan and ramipril show synergistic cardiorenal protective effects in a type 2 diabetic mouse model.

19 August 2019 in European Journal of Neurology
Verified
Journal Article
Closed access
PDF file
ECElisa Cuadrado
Elisa Cuadrado
BBBegoña Benito
Begoña Benito
AOAngel Ois
Angel Ois
EVErmengol Valles
Ermengol Valles
ARAna Rodríguez-Campello
Ana Rodríguez-Campello
JRJaume Roquer
Jaume Roquer

2 August 2021 in Journal of Cardiovascular Translational Research
Verified
Journal Article
Closed access
PDF file
NMNatalia Mateos
Natalia Mateos
MGMiquel Gómez
Miquel Gómez
AHArianna Homar
Arianna Homar
AGAnna Garcia-Elias
Anna Garcia-Elias
LYLaia Yáñez
Laia Yáñez
BBBegoña Benito
Begoña Benito

9 May 2024 in Basic Research in Cardiology
Verified
Journal Article
Closed access
PDF file
MPMarta Consegal Pérez
Marta Consegal Pérez
EMElisabet Miró-Casas
Elisabet Miró-Casas
IBIgnasi Barba
Ignasi Barba
MRMarisol Ruiz-Meana
Marisol Ruiz-Meana
JIJavier Inserte
Javier Inserte
Antonio Rodriguez-SinovasAntonio Rodriguez-Sinovas
Antonio Rodriguez-Sinovas

1 December 2014 in International Journal of Cardiology
Verified
Journal Article
Closed access
EVErmengol Valles
Ermengol Valles
VBVictor Bazan
Victor Bazan
MCMiguel Cainzos-Achirica
Miguel Cainzos-Achirica
MJMiguel Eduardo Jáuregui
Miguel Eduardo Jáuregui
BBBegoña Benito
Begoña Benito
JMJulio Marti-Almor
Julio Marti-Almor

26 November 2009
Verified
Book Chapter
Closed access
PDF file
BBBegoña Benito
Begoña Benito
RBRamon Brugada
Ramon Brugada
JBJosep Brugada
Josep Brugada
PBPedro Brugada
Pedro Brugada